We have changed our visitation policy for the safety of our patients and staff. Click here for the updated visitation policy and click here for information about COVID-19.

[LCID Study Number: 2017-085CIRB]

S1613: A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (MCRC) with HER-2 Amplification

The purpose of this study is to compare any good and bad effects of using a combination of antibodies, trastuzumab and pertuzumab, to using the usual chemotherapy, cetuximab and irinotecan, in patients with advanced colorectal cancer that cannot be removed by surgery.

Primary Contact Email: [email protected]

Primary Contact Phone: 781-744-3055